A new drug, loberamisal, has demonstrated in a large-scale clinical trial that it can meaningfully improve recovery for individuals experiencing an ischaemic stroke. The findings, published in JAMA in September 2026, represent the first time a neuroprotective treatment has shown statistically significant benefits in clinical trials for mild to moderate cases of the condition.
The drug underwent testing in a double-blind, placebo-controlled trial involving 998 patients across 32 hospitals in China between July 2024 and April 2025. Led by Dr. Suya Li of Beijing Tiantan Hospital, the study focused on patients treated within 48 hours of their stroke. Results indicated that loberamisal increased the proportion of patients achieving full functional recovery—defined as a modified Rankin scale score of 0 or 1—from 56.3% in the placebo group to 69.7% in the treatment group. This translates to a 12% reduction in patients who would otherwise have faced even slight disability.
The drug’s effectiveness proved most pronounced in patients whose treatment was delayed beyond the ideal window of a few hours, suggesting it extends the timeframe for effective intervention. Existing stroke treatments, such as thrombolytics or mechanical clot removal, require rapid blood flow restoration to damaged brain tissue, but these methods only work within a narrow timeframe. In contrast, loberamisal appears to protect neurons from oxygen deprivation damage and may promote neurogenesis, aiding brain repair even when standard treatments arrive too late.
How the trial rigorously tested loberamisal
The trial employed rigorous design principles, including intention-to-treat analysis, which ensured all participants, even those who dropped out, were included in the final results. This approach better reflects real-world conditions, where patients may not always complete full treatment. The study excluded patients with severe strokes or those undergoing surgery, focusing instead on mild to moderate cases (NIHSS scores between 7 and 20).
Participants were randomly assigned to receive either 40 mg of loberamisal intravenously for 10 days or a placebo infusion. After 90 days, researchers evaluated outcomes using the modified Rankin scale, which ranges from 0 (no symptoms) to 5 (bedridden). The drug did not produce significant adverse effects, and mortality rates were marginally lower in the treatment group.
Most participants were men, accounting for two-thirds of the cohort, with a median age of 64 and a median BMI of 24. The trial’s strict inclusion criteria and careful patient matching helped isolate the drug’s effects, minimizing bias risks.
The study’s focus on mild to moderate cases, defined by NIHSS scores between 7 and 20, reduced confounding variables, as surgical interventions carry distinct recovery trajectories. Researchers also ensured participants had no prior significant disability (modified Rankin score of 0 or 1 before the stroke), allowing direct attribution of improvements to loberamisal. Patient demographics mirrored real-world stroke patterns in China, where hypertension is a leading risk factor, though further testing is needed for populations with different health profiles.
Why loberamisal works even after missed treatment windows
The median NIHSS score of 8 indicated most participants experienced mild to moderate symptoms, such as slurred speech or mild weakness, rather than severe paralysis or cognitive deficits. This focus enabled measurement of subtle but meaningful improvements, including a 13% reduction in placebo patients who would have scored a 2 (slight disability) but instead achieved a 1 (no significant disability) after receiving the drug.
Animal studies suggest loberamisal operates through multiple mechanisms, blocking NMDAR-mediated excitotoxicity, the process where overstimulated neurons self-destruct during oxygen deprivation, while also promoting neurogenesis, or the growth of new brain cells. Early biomarker analysis indicates reduced neuroinflammation, a process often worsening damage after a stroke. These mechanisms may explain why the drug’s benefits were most pronounced in patients treated between 12 and 48 hours post-stroke, a window where standard treatments like thrombolytics are far less effective. Even among those treated within 12 hours, the drug modestly improved outcomes, suggesting it could complement existing therapies rather than replace them.
The trial’s safety profile was a key strength, with adverse events comparable between the drug and placebo groups. Mortality rates were slightly lower in the loberamisal cohort, aligning with preclinical data showing no major toxic effects. Only 14 participants in the treatment group and 20 in the placebo group discontinued early, primarily due to unrelated factors such as additional medications or logistical issues rather than side effects.